Daniel Yick Chin Heng

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2014 · 231 citations

Medicine, Oncology, Pharmacotherapy +17

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

Patrick Cheung, Samir Patel, Scott North et al. · European Urology · 2021 · 125 citations

Medicine, Oncology, Radiation Oncology +16

Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2015 · 66 citations

Medicine, Oncology, Pharmacology +17

Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Shaan Dudani, Guillermo de Velasco, Connor Wells et al. · Journal of Clinical Oncology · 2020 · 31 citations

Medicine, Biostatistics, Oncology +12

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

Georg A. Bjarnason, Jennifer J. Knox, Christian Kollmannsberger et al. · European Journal of Cancer · 2019 · 28 citations · Full text

Medicine, Oncology, Pharmacology +16